← Back to Search

Beta-2 Adrenergic Receptor Agonist

Formoterol Fumarate for Type 2 Diabetes and Obesity (GB10 Trial)

N/A
Waitlist Available
Led By André C. Carpentier, M.D.
Research Sponsored by Université de Sherbrooke
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured 60 minutes before and 90 minutes after cold exposure (a) and 30 minutes after inhalation of fumarate formoterol (b and c)
Awards & highlights

GB10 Trial Summary

This trial is testing if a drug called formoterol fumarate can help people with obesity and Type 2 diabetes by activating their brown adipose tissue.

Eligible Conditions
  • Obesity
  • Type 2 Diabetes

GB10 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured 60 minutes before and 90 minutes after cold exposure (a) and 30 minutes after inhalation of fumarate formoterol (b and c)
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured 60 minutes before and 90 minutes after cold exposure (a) and 30 minutes after inhalation of fumarate formoterol (b and c) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Brown Adipose Tissue thermogenesis (formoterol induced, cold-induced and effect of nicotinic acid)
Secondary outcome measures
BAT triglyceride content
Brown Adipose Tissue (BAT) glucose uptake
Nonesterified Fatty Acids
+7 more

GB10 Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Formoterol without nicotinic acidExperimental Treatment5 Interventions
Formoterol fumarate or Oxeze® Turbuhaler®: 48 µg (4 inhalations of 12 µg).
Group II: Formoterol with nicotinic acidExperimental Treatment6 Interventions
Formoterol fumarate or Oxeze® Turbuhaler®: 48 µg (4 inhalations of 12 µg). Nicotinic acid or Niacin: repeated doses of 150 MG every 30 minutes, for 3 hours.
Group III: Acute Cold ExposureActive Control7 Interventions
3h-acute cold exposure.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
iv lines
2022
N/A
~20
Formoterol Fumarate 12 micrograms Inhalation Powder
2022
N/A
~20
Nicotinic Acid 50 MG Oral Tablet
2022
N/A
~20
Positron Emission Tomography (PET)
2018
Completed Phase 4
~1390
Indirect calorimetry
2015
Completed Phase 4
~870
Biopsy
2014
Completed Phase 4
~1090

Find a Location

Who is running the clinical trial?

Université de SherbrookeLead Sponsor
298 Previous Clinical Trials
69,929 Total Patients Enrolled
14 Trials studying Obesity
2,673 Patients Enrolled for Obesity
André C. Carpentier, M.D.Principal InvestigatorUniversité de Sherbrooke

Media Library

Formoterol Fumarate (Beta-2 Adrenergic Receptor Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT05553184 — N/A
Obesity Research Study Groups: Acute Cold Exposure, Formoterol with nicotinic acid, Formoterol without nicotinic acid
Obesity Clinical Trial 2023: Formoterol Fumarate Highlights & Side Effects. Trial Name: NCT05553184 — N/A
Formoterol Fumarate (Beta-2 Adrenergic Receptor Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05553184 — N/A
~4 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top